ENTPD1 and cancer: Indeed, blocking CD39 in vivo with specific antagonists or monoclonal antibodies currently in preclinical development has been suggested as an immunomodulatory intervention to enhance effector T-cell responses in HIV infection [37,38] and in cancer [40].